Your contact for new licenses
The US pharmaceutical company Pfizer has renegotiated a contract from 2021 with the EU Commission. According to media reports, several hundred million euros in cancellation fees are at stake for Germany alone. The European Parliament wants to clarify the background. But instead of answers, Pfizer sends a catalog of questions.
By Eric Bonse
The war in Ukraine, inflation and rising interest rates: the EU's financial framework is not designed to cope with all this. Nevertheless, the Commission is unlikely to ask the member states for a large additional payment. The sovereignty fund will thus not be a great success.
By Till Hoppe